RT Journal Article
SR Electronic
T1 Wastewater sample site selection to estimate geographically-resolved community prevalence of COVID-19: A research protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.23.20180224
DO 10.1101/2020.08.23.20180224
A1 Ray A. Yeager
A1 Rochelle H. Holm
A1 Kumar Saurabh
A1 Joshua L Fuqua
A1 Daymond Talley
A1 Aruni Bhatnagar
A1 Ted Smith
YR 2020
UL http://medrxiv.org/content/early/2020/08/25/2020.08.23.20180224.abstract
AB Background Wastewater monitoring for virus infections within communities can complement conventional clinical surveillance. Currently, most SARS-CoV-2 testing is performed during clinical encounters with symptomatic individuals, and therefore likely underrepresents actual population prevalence. Randomized testing on a regular basis to estimate population-level infection rates is prohibitively costly and is hampered by a range of barriers associated with participation in clinical research. In comparison, community-level fecal monitoring can be performed through wastewater surveillance and can effectively surveil communities with less temporal lag than other surveillance methods. However, epidemiologically-defined protocols for wastewater sample site selection are lacking.Methods Herein we describe methods for developing a geographically-resolved population-level wastewater sampling approach in Jefferson County, Kentucky which may have general applicability for cities throughout the United States. This approach was developed by the selection of sampling locations along sewer lines transporting raw wastewater from geographically and demographically distinct areas that correspond with locations where random testing of residents occurs.Conclusions Development of this protocol for population-level sampling for SARS-CoV-2 prevalence in wastewater can be utilized to inform consistent wastewater monitoring among cities for up-to-date and geographically-resolved information on COVID-19 prevalence within communities. This information could substantially supplement public health surveillance of COVID-19 and thus serve to better guide targeted mitigation strategies throughout the United States.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by grants from the James Graham Brown Foundation and the Owsley Brown Family Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This population health research is not subject to IRB review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.